Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1. ...

Abt Associates is a global leader in research, evaluation and program implementation; driving innovation and measurable impact for more than 50 years. What sets us apart is our evidence-based and ...

The outlook and technical action suggest Abbott Laboratories (NYSE:ABT) will lead healthcare names like Johnson & Johnson (NYSE:JNJ) higher in 2025. While each produced a solid quarter ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoPrecise Antibodies (IPA – Research ...